Products and Research
Develop innovative drugs to safeguard human health
Products
- M701（EpCAM×CD3 BsAb ）
- Y400 （VEGFxANG2 BsAb）
- Y332（VEGF×TGF-β BsAb）
- Y225（FIXa×FX BsAb）
- Y232（TL1A×X BsAb）
- Y180（MHC-II）
M701（EpCAM×CD3 BsAb ）
Product Features and Advantages
- Mainly used for palliative care primarily for the treatment of malignant ascites（MA）and Malignant pleural effusion（MPE）derived from EpCAM-positive cancer；
- Catumaxomab with the same targets had been used clinically for MA,and the efficacy was obvious ;
- A Phase II clinical trial of M701 in treating malignant ascites(MA) and a Phase Ib/II clinical trial of M701 in treating malignant pleural effusion(MPE) is currently conducting.
- In May 2026, the NMPA accepted the NDA of M701 for the treatment of MA.
Y400 （VEGFxANG2 BsAb）
Product Features and Advantages
- Mainly used for wet age-related macular degeneration, with 3.9 million patients in China in 2021 statistically and approximately 20 million patients in China and huge market；
- Dual blockade of VEGF and ANG2, providing a stronger therapeutic mechanism；
- Ultra-high concentration formulation of 140mg/ml for intravitreal injection；
- On July 26, 2022, YZYBIO entered into an asset transfer agreement with Shenzhen Kangzhe Vision Pharmaceutical Development Co.,Ltd. (深圳市康哲维盛医药发展有限责任公司)(“CMS Vision”), to transfer all the rights and assets relating to Y400 to CMS Vision.
Y332（VEGF×TGF-β BsAb）
Product Features and Advantages
- Being developed for the treatment of a variety of solid tumors;
- In preclinical studies, Y332 showed high affinity to both VEGF and TGF-β, favorable bioactivity and stability, and demonstrated certain anti-tumor effects；
- The company is continuing to explore the feasibility of Y332 in combination with chemotherapy or ADCs for the treatment of specific tumour types；
Y225（FIXa×FX BsAb）
Product Features and Advantages
- a biosimilar of Emicizumab for the treatment of hemophilia；
- Y225 has completed registration and production and IND submission, and has obtained clinical approval. We submitted a patent application for the Y225 formulation to the China National Intellectual Property Administration, and such patent has been granted；
Y232（TL1A×X BsAb）
Product Features and Advantages
- An antibody for the treatment of inflammatory bowel disease targeting TL1A, which can inhibit the inflammatory signaling pathway to effectively alleviate the occurrence and development of inflammation；
- It is currently in negotiation with an external party for joint development of mAbs oral preparation；
Y180（MHC-II）
Product Features and Advantages
- A soluble LAG-3-Fc fusion protein developed for anti-tumor immunotherapy. It specifically binds to HLA class II molecules on the surface of antigen-presenting cells (APC), thereby promoting APC activation, antigen presentation, and T-cell immune priming, which in turn enhances anti-tumor immune response；
- Based on its APC immune-amplification mechanism, Y180 has the potential to be developed in combination with PD-1/PD-L1 inhibitors, radiotherapy/chemotherapy, ADC, and other therapies；
Patient Recruitment
Products
Indications
Name of the Trial
Phone：
027-82668988
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
Share
